PharmCube's presents the most groundbreaking translational medicine targets of 2024, showcasing innovations—from novel immune checkpoints to cutting-edge gene therapies—that are reshaping drug discovery across oncology, immunology and rare diseases. This year's report features 25 targets, including new discoveries, clinical proof-of-concept validations and emerging technologies. With growing contributions from Chinese researchers, this report underscores the global impact of translational medicine in addressing unmet medical needs while offering actionable insights for investments, partnerships and staying ahead in pharmaceutical R&D.

With the advancement of centralised procurement and hospital entry barriers for medicines, the out-of-hospital market is emerging as a key strategic focus for pharmaceutical companies evaluating new opportunities. Amid this industry transformation, both drug developers and retail pharmacies must proactively adapt to shifting dynamics and capitalise on evolving trends.

Navigating the extensive collection of 7,000+ abstracts for the upcoming AACR Annual Meeting can be a daunting task. To streamline your experience PharmCube has meticulously compiled and curated every abstract into a structured, filterable spreadsheet. This resource allows you to efficiently search by disease, therapy, target, affiliation, and other key criteria.

PharmCube analyses global drug development data published as of February 28, 2025, listing a total of 21 major R&D events. These include 1 market approval, 18 clinical and preclinical progress updates, and 2 special review status awards.

PharmCube analyses global drug development data published as of January 31, 2025, listing a total of 23 major R&D events. These include 4 drug approvals, 17 clinical progress changes, and 2 spe- cial review status awards. They are sorted below by therapeutic area and date of publication.

PharmCube analyses global drug development data published as of March 31, 2025, listing a total of 26 major R&D events. These include 4 market approvals, 21 clinical and preclinical progress updates, and 1 special review status award